Available online at www. scholarsresearchlibrary.com

Scholars Research Library

Der Pharmacia Lettre, 2023, 15(4): 17-18
(http: //scholarsresearchlibrary. com/archive. html)

ISSN 0975-5071
USA CODEN: DPLEB4

Unraveling the Mechanisms of DEK Protein in Hematopoiesis and Acute Myeloid Leukemia Progression

Ethan Williams*

Department of Pathology, Massachusetts General Hospital, Boston, United States of America

***Corresponding author:** Ethan Williams, Department of Pathology, Massachusetts General Hospital, Boston, United States of America; E-mail: ethanwilliams@gmail.com*

***Received:** 30-Mar-2023, Manuscript No. DPL-23-98854; **Editor assigned:** 03-Apr-2023, PreQC No. DPL-23-98854 (PQ); **Reviewed:** 17-Apr-2023, QC No.DPL-23-98854; **Revised:** 24-Apr-2023, Manuscript No. DPL-23-98854 (R); **Published:** 01-May-2023, DOI: 10.37532/dpl.2023.15.17.*

DESCRIPTION

The DEK protein is a chromatin-binding protein that plays a critical role in gene regulation and chromatin organization. Dysregulation of DEK expression and function has been implicated in the development of various types of cancer, including Acute Myeloid Leukemia (AML). This study will discuss the impact of the chromatin-binding DEK protein in hematopoiesis and AML.

Hematopoiesis is the process by which blood cells are produced in the bone marrow. It is a complex and tightly regulated process that involves the differentiation of hematopoietic stem cells into various blood cell lineages, including erythrocytes, platelets, and white blood cells. The DEK protein has been shown to play a critical role in hematopoiesis by regulating the expression of genes involved in this process. Studies have demonstrated that DEK is required for the self-renewal of hematopoietic stem cells and the differentiation of myeloid cells.

In addition to its role in hematopoiesis, the DEK protein has been implicated in the development of AML. The AML is a type of blood cancer that arises from abnormal myeloid progenitor cells in the bone marrow. AML is characterized by the uncontrolled proliferation of immature myeloid cells, which leads to the suppression of normal blood cell production. The overexpression of DEK has been observed in a significant proportion of AML patients, and several studies have shown that DEK plays a critical role in the development and progression of this disease.

One of the ways in which DEK contributes to AML is by promoting the self-renewal of leukemic stem cells. Leukemic stem cells are thought to be responsible for the initiation and maintenance of AML, and their persistence is a major cause of relapse in AML patients. Studies have demonstrated that DEK is required for the self-renewal of leukemic stem cells and that its overexpression leads to the expansion of these cells. DEK also plays a role in the regulation of apoptosis, which is the programmed cell death that occurs in response to various cellular stressors. Apoptosis is a critical mechanism for maintaining normal cellular homeostasis and preventing the development of cancer. DEK has been shown to inhibit apoptosis by interacting with and inhibiting the function of several pro-apoptotic proteins, including p53 and Bax. The inhibition of apoptosis by DEK promotes the survival of leukemic cells and contributes to the development and progression of AML.

In addition to its role in leukemic stem cells and apoptosis, DEK has also been shown to regulate the expression of genes involved in Deoxyribonucleic acid (DNA) repair and chromatin remodeling. These processes are critical for maintaining genomic stability and preventing the accumulation of mutations that can lead to the development of cancer. DEK has been shown to interact with several proteins involved in DNA repair and chromatin remodeling, including the SWItch/Sucrose Non-Fermentable (SWI/SNF) complex and the nucleotide excision repair factor Xeroderma Pigmentosum Complementation (XPC). Dysregulation of these processes by DEK can lead to the accumulation of mutations and the development of cancer.

Several studies have demonstrated the potential of DEK as a therapeutic target for the treatment of AML. The inhibition of DEK expression or function has been shown to impair the self-renewal of leukemic stem cells and induce their differentiation into more mature myeloid cells. Additionally, the inhibition of DEK has been shown to sensitize leukemic cells to chemotherapy and radiation therapy, suggesting that targeting DEK could improve the efficacy of these treatments.

The DEK protein plays a critical role in hematopoiesis and the development of AML. Dysregulation of DEK expression and function contributes to the development and progression of AML by promoting the self-renewal of leukemic stem cells, inhibiting apoptosis, and dysregulating DNA repair and chromatin remodeling. Targeting DEK has emerged as a potential therapeutic strategy for the treatment of AML, with several studies demonstrating the efficacy of DEK inhibition in inducing leukemic cell differentiation and sensitizing them to chemotherapy and radiation therapy.

However, it is important to note that DEK plays a critical role in normal hematopoiesis as well, and its inhibition could potentially lead to unwanted side effects, such as cytopenias and immunodeficiency. Therefore, more research is needed to develop targeted approaches that can selectively inhibit DEK function in leukemic cells without affecting normal hematopoiesis. Overall, the study of DEK and its role in hematopoiesis and AML has provided important insights into the molecular mechanisms underlying these processes and has identified DEK as a potential therapeutic target for the treatment of AML. Further research in this area has the potential to lead to the development of novel and more effective treatments for this devastating disease.